| Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia S Li, FE Garrett-Bakelman, SS Chung, MA Sanders, T Hricik, F Rapaport, ... Nature medicine 22 (7), 792-799, 2016 | 385 | 2016 |
| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 374 | 2021 |
| Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations SD Freeman, RK Hills, P Virgo, N Khan, S Couzens, R Dillon, A Gilkes, ... Journal of Clinical Oncology 36 (15), 1486-1497, 2018 | 196 | 2018 |
| Molecular MRD status and outcome after transplantation in NPM1-mutated AML R Dillon, R Hills, S Freeman, N Potter, J Jovanovic, A Ivey, AS Kanda, ... Blood, The Journal of the American Society of Hematology 135 (9), 680-688, 2020 | 135 | 2020 |
| Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia C Craddock, A Jackson, J Loke, S Siddique, A Hodgkinson, J Mason, ... Journal of Clinical Oncology 39 (7), 768-778, 2021 | 112 | 2021 |
| Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML F Basheer, G Giotopoulos, E Meduri, H Yun, M Mazan, D Sasca, ... Journal of Experimental Medicine 216 (4), 966-981, 2019 | 102 | 2019 |
| Unified classification and risk-stratification in acute myeloid leukemia Y Tazi, JE Arango-Ossa, Y Zhou, E Bernard, I Thomas, A Gilkes, ... Nature Communications 13 (1), 1-16, 2022 | 86 | 2022 |
| Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia IS Tiong, R Dillon, A Ivey, TC Teh, P Nguyen, N Cummings, DC Taussig, ... British journal of haematology 192 (6), 1026-1030, 2021 | 73 | 2021 |
| Factors affecting COVID-19 outcomes in cancer patients: a first report from guy's cancer center in London B Russell, C Moss, S Papa, S Irshad, P Ross, J Spicer, S Kordasti, ... Frontiers in oncology 10, 1279, 2020 | 69 | 2020 |
| Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in … P Harrington, KJ Doores, D Radia, A O’Reilly, HPJ Lam, J Seow, ... British journal of haematology 194 (6), 999-1006, 2021 | 64 | 2021 |
| Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia A Kühnl, PJM Valk, MA Sanders, A Ivey, RK Hills, KI Mills, RE Gale, ... Blood, The Journal of the American Society of Hematology 125 (19), 2985-2994, 2015 | 58 | 2015 |
| Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial N Russell, A Burnett, R Hills, S Betteridge, M Dennis, J Jovanovic, ... Blood, The Journal of the American Society of Hematology 132 (13), 1452-1454, 2018 | 57 | 2018 |
| Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis AG Rowan, R Dillon, A Witkover, A Melamed, MA Demontis, NA Gillet, ... Blood, The Journal of the American Society of Hematology 135 (23), 2023-2032, 2020 | 53 | 2020 |
| Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative … P Harrington, H de Lavallade, KJ Doores, A O’Reilly, J Seow, C Graham, ... Leukemia 35 (12), 3573-3577, 2021 | 46 | 2021 |
| Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome S Loo, R Dillon, A Ivey, NS Anstee, J Othman, IS Tiong, N Potter, ... Blood, The Journal of the American Society of Hematology 140 (22), 2407-2411, 2022 | 40 | 2022 |
| Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients P Harrington, KJ Doores, C Saha, J Saunders, F Child, R Dillon, ... Cancer cell 39 (11), 1448-1449, 2021 | 38 | 2021 |
| Lyme disease in the UK: clinical and laboratory features and response to treatment R Dillon, S O’Connell, S Wright Clinical medicine 10 (5), 454-457, 2010 | 38 | 2010 |
| How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML) R Dillon, N Potter, S Freeman, N Russell British Journal of Haematology 193 (2), 231-244, 2021 | 37 | 2021 |
| 2021 update measurable residual disease in acute myeloid leukemia: European leukemia net working party consensus document M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood 138 (26), 2753-2767, 2021 | 37 | 2021 |
| The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia JV Jovanovic, MC Chillon, C Vincent-Fabert, R Dillon, E Voisset, ... Leukemia 31 (3), 747-751, 2017 | 31 | 2017 |
